Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Acm Biolabs Pte. Ltd. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners and are being reviewed in multiple art units. This suggests that the company's active applications cover different technical aspects or sub-specialties within the biotechnology field, as they are not being handled by the same art unit or examiner.
YU, DAVID TUYANG is the busiest examiner for this portfolio, currently overseeing 1 pending office action. With the current workload divided between different individuals, the applicant must navigate the unique procedural styles of different examiners. This distribution across the distinct art units means the prosecution strategy for Acm Biolabs Pte. Ltd. should be tailored to the specific requirements of both the busiest examiner and the other distinct examiner involved to achieve favorable outcomes in this complex technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264046 | SOLE USE OF POLYMERSOME ASSOCIATED ADJUVANT FOR STIMULATING AN IMMUNE RESPONSE | YU, DAVID TUYANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17276023 | POLYMERSOMES COMPRISING A COVALENTLY BOUND ANTIGEN AS WELL AS METHODS OF MAKING AND USES THEREOF | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264046 | SOLE USE OF POLYMERSOME ASSOCIATED ADJUVANT FOR STIMULATING AN IMMUNE RESPONSE | YU, DAVID TUYANG | 1635 | §102§103§112 | Non-Final OA | — | Pending | Aug 02, 2023 |
| 17276023 | POLYMERSOMES COMPRISING A COVALENTLY BOUND ANTIGEN AS WELL AS METHODS OF MAKING AND USES THEREOF | HOERNER, PAUL ELLSWORTH | 1611 | §103 | Final Rejection | — | Pending | Mar 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial